



Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
KESIMPTA (Ofatumumab) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **KESIMPTA (Ofatumumab)**. Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: <http://www.providers.kaiserpermanente.org/mas/formulary.html>

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Prescriber Information

Is the prescriber a Neurologist? No Yes

If consulted with a specialist, specialist name and specialty: _____

Prescriber Name: _____ Specialty: _____ NPI: _____

Prescriber Address: _____

Prescriber Phone #: _____ Prescriber Fax #: _____

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #: _____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____

Sig: _____

Drug 2: Name/Strength/Formulation: _____

Sig: _____

5– Diagnosis/Clinical Criteria

1. Is this request for initial or continuing therapy?
 Initial therapy Continuing therapy, State date: _____
2. Indicate the Member’s diagnosis for the requested medication: _____
3. Does the member have a diagnosis of relapsing form of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting, active secondary progressive disease)? **AND**
 No Yes
4. Member is not on another DMT? **AND**
 No Yes
5. Member has failed an adequate trial (≥3 months) of, or has a documented allergy or intolerance to, or is not a candidate for Truxima (rituximab-abbs)? **AND**
6. Member has failed an adequate trial (≥3 months) of, or has a documented allergy or intolerance to, or is not a candidate for Ocrevus?
 No Yes

For Continuation of Therapy, Please Respond to Additional Questions Below:

1. Does member continue to meet criteria listed above? **AND**
 No Yes
2. Member has completed the following laboratory monitoring within the last 6 months:
 - a. Quantitative serum immunoglobulins
 - b. Complete blood count with differential
 - c. Liver function No Yes

6 – Prescriber Sign-Off

Additional Information – Please submit chart notes/medical records for the patient that are applicable to this request. Provide any additional supporting information that should be taken into consideration:

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:

Date:

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility